Autoimmunity in primary immune deficiency: taking lessons from our patients

Area of Science:

• Immunology
• Genetics
• Autoimmunity

Background:

• Immune system gene mutations cause functional deficits, impacting self-tolerance and leading to autoimmunity.
• Defects in apoptosis, self-reactive cell clearance, and regulatory T cells contribute to autoimmune disorders.
• While X-linked agammaglobulinaemia patients rarely develop autoimmunity, B cell dysfunction in other antibody deficiencies significantly increases autoimmune incidence.

Purpose of the Study:

• To explore the molecular underpinnings of immune defects and their connection to autoimmune diseases.
• To investigate the specific B cell characteristics associated with autoimmunity in common variable immune deficiency (CVID).
• To evaluate treatment strategies for autoimmune cytopenias in CVID patients.

Main Methods:

• Analysis of genetic mutations affecting immune system components.
• Characterization of B cell phenotypes, including apoptosis, proliferation, and Toll-like receptor signaling in CVID patients.
• Review of treatment outcomes for autoimmune cytopenias using immunoglobulin, steroids, and rituximab.

Main Results:

• Immune defects, particularly B cell dysfunction, are strongly associated with autoimmune diseases, especially antibody deficiencies.
• Common variable immune deficiency patients with specific peripheral blood memory B cell phenotypes exhibit increased susceptibility to cytopenias.
• These B cells show autoimmune potential, impaired somatic hypermutation, reduced proliferation, accelerated apoptosis, and abnormal Toll-like receptor signaling.
• High-dose immunoglobulin and steroids offer some benefit, while rituximab shows promise for refractory cytopenias, even with repeated use.

Conclusions:

• Understanding genetic immune defects is crucial for deciphering autoimmunity.
• Specific B cell abnormalities in CVID contribute significantly to autoimmune cytopenias.
• Rituximab, alongside immunoglobulin therapy, presents a viable treatment option for refractory autoimmune cytopenias in CVID.